Physician profile
Edward Lin
NPI 1235155961
$13,857.05
in general payments reported to CMS, 2019-2025
10 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 77% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $1,512 · 2021: $14.52 · 2022: $205 · 2024: $10K · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $892 · Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,147.75 |
| Travel and Lodging | $891.71 |
| Food and Beverage | $615.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $10,170.91 | 2024 | |
| Heron Therapeutics, INC. | $1,400.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,074.00 | 2025 | Imfinzi |
| Asensus Surgical, INC. | $398.89 | 2019 | |
| Intra-Sana Laboratories | $198.68 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Intuitive Surgical, INC. | $190.65 | 2019-2024 | |
| W. L. Gore & Associates, INC. | $156.41 | 2020-2022 | |
| Teleflex LLC | $155.84 | 2025 | Titan Sgs Bailout Chuck |
| Conmed Corporation | $93.56 | 2020 | |
| Boston Scientific Corporation | $18.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.